We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cepheid

News List

Cepheid Receives CE-IVD Registration for SARS-CoV-2, Flu A, Flu B, RSV Combination Test americanpharmaceuticalreview
December 10, 2020
Cepheid announced the CE-IVD marking of Xpert® Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample.
Cepheid Receives EUA for SARS-CoV-2, Flu A, Flu B and RSV Combination Test americanpharmaceuticalreview
October 09, 2020
Cepheid has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19 ...
Cepheid Announces Development of Combination Test for SARS-CoV-2, Flu A, Flu B, RSV americanpharmaceuticalreview
June 18, 2020
Cepheid announced the development of a next-generation test to assist global efforts in the fight against the spread of COVID-19 during the upcoming respiratory virus season.
Cepheid Receives Emergency Use Authorization for Rapid SARS-CoV-2 Test americanpharmaceuticalreview
March 25, 2020
Cepheid has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2.